Comparative Diagnostic Accuracy of LF-LAM TB Antigen and Xpert MTB/RIF in Pulmonary Tuberculosis among Underweight Patients
DOI:
https://doi.org/10.36497/7brxv447Keywords:
diagnostic, LF-LAM TB-Ag, screening, tuberculosis, Xpert MTB/RifAbstract
Background: In 2023, the global incidence of tuberculosis (TB) reached 8.2 million cases. It is the highest on record due to delayed diagnoses and a rising number of TB patients. Tuberculosis is more prevalent among patients with compromised immune systems, including those with HIV and malnutrition (BMI <18.5 kg/m2), who exhibit increased vulnerability to infection. The challenge of sputum expulsion impedes diagnosis, requiring a rapid, cost-effective early-detection technique. The lateral flow lipoarabinomannan TB antigen (LF-LAM TB-Ag) assay provides an alternate method for identifying lipoarabinomannan in urine, a constituent of the Mycobacterium tuberculosis cell wall. This study assessed the effectiveness of the LF-LAM TB-Ag assay compared with the Xpert MTB/RIF assay for TB diagnosis.
Methods: A comparative cross-sectional study was conducted at Abdul Moeloek Hospital, Lampung Province, from January 2023 to June 2024. A total of 52 suspected pulmonary TB patients with HIV-negative status and underweight BMI were evaluated using both the LF-LAM TB-Ag and Xpert MTB/RIF assays.
Results: Chi-square tests were used to compare the performance of LF-LAM TB-Ag with Xpert MTB/RIF. The LF-LAM TB-Ag test had a sensitivity of 79.59% and a specificity of 100% (P=0.002).
Conclusion: This study underscores the necessity for early detection of pulmonary TB in underweight individuals. The integration of LF-LAM TB-Ag with Xpert MTB/RIF improves detection, especially in high-risk populations, enabling prompt treatment and enhanced disease management.
Downloads
References
1. World Health Organization. Global tuberculosis report 2024. Geneva; 2024.
2. Kementerian Kesehatan RI. Profil kesehatan Indonesia 2023. Jakarta: Kementerian Kesehatan RI; 2024.
3. Maaz M, Sultan MT, Okoduwa SIR, Khalid MU, Asif A, Rafique M, et al. The association and interactions of malnutrition, micronutrients, and drug therapy in the management of tuberculosis. World Nutrition. 2024;15(2):102–14.
4. Chandrasekaran P, Saravanan N, Bethunaickan R, Tripathy S. Malnutrition: Modulator of immune responses in tuberculosis. Front Immunol. 2017;8:1316.
5. Feleke BE, Feleke TE, Biadglegne F. Nutritional status of tuberculosis patients, a comparative cross-sectional study. BMC Pulm Med. 2019;19(1):182.
6. Harjatmo TP, Par’i H, Wiyono S. Bahan ajar gizi: Penilaian status gizi. Jakarta: Badan PPSDM Kementerian Kesehatan RI; 2017.
7. Cepheid. Xpert® MTB/RIF. 2020.
8. Pramana PHI, Dwija IBNP, Hendrayana MA. Spesifisitas dan sensitifitas pemeriksaan mikroskopis TBC dibandingkan pemeriksaan kultur TBC pada pasien tuberkulosis di Rumah Sakit Umum Pusat Sanglah periode Januari–Desember 2015. Jurnal Medika Udayana. 2021;10(6):79–84.
9. Perhimpunan Dokter Paru Indonesia. Tuberkulosis: Pedoman diagnosis dan penatalaksanaan di Indonesia. 2nd ed. Isbaniah F, Burhan E, Sinaga BYM, Yanifitri DB, Handayani D, Harsini, et al., editors. Jakarta: Perhimpunan Dokter Paru Indonesia; 2021.
10. Ricks S, Denkinger CM, Schumacher SG, Hallett TB, Arinaminpathy N. The potential impact of urine-LAM diagnostics on tuberculosis incidence and mortality: A modelling analysis. PLoS Med. 2020;17(12):e1003466.
11. Kusumawardani A, Yanfaunnas AM, Supandi DP, Inggita RAM, Andayani NGAAPT, Louisa M, et al. The use of urinary lipoarabinomannan (LAM) as a rapid diagnostic test for adult pulmonary tuberculosis in HIV-positive patients: An evidence-based case report. Journal of International Dental and Medical Research. 2021;14(1):461–6.
12. Liu H, Gui X, Chen S, Fu W, Li X, Xiao T, et al. Structural variability of lipoarabinomannan modulates innate immune responses within infected alveolar epithelial cells. Cells. 2022;11(3):361.
13. Bulterys MA, Wagner B, Redard-jacot M, Suresh A, Pollock NR, Moreau E, et al. Point-of-care urine LAM tests for tuberculosis diagnosis: A status update. J Clin Med. 2020;9(1):111.
14. World Health Organization. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV. Https://Iris.Who.Int/Bitstream/Handle/10665/329479/9789241550604-Eng.Pdf?Sequence=1. Geneva; 2019. p. 1–44.
15. Tessema TA, Bjune G, Assefa G, Svenson S, Hamasur B, Bjorvatn B. Clinical and radiological features in relation to urinary excretion of lipoarabinomannan in Ethiopian tuberculosis patients. Scand J Infect Dis. 2002;34(3):167–71.
16. Marçôa R, Ribeiro AI, Zão I, Duarte R. Tuberculosis and gender – Factors influencing the risk of tuberculosis among men and women by age group. Pulmonology. 2018;24(3):199–202.
17. Peer V, Schwartz N, Green MS. Gender differences in tuberculosis incidence rates—A pooled analysis of data from seven high-income countries by age group and time period. Front Public Health. 2023;10:997025.
18. Cho SH, Lee H, Kwon H, Shin DW, Joh HK, Han K, et al. Association of underweight status with the risk of tuberculosis: A nationwide population-based cohort study. Sci Rep. 2022;12:16207.
19. Elhalawany N, Shalaby N, Fathy A, Elmorsy AS, Zaghloul M, El-shahawy H, et al. Role of detection of lipoarabinomannan (LAM) in urine for diagnosis of pulmonary tuberculosis in HIV patients: Egyptian experience. The Egyptian Journal of Bronchology. 2021;15:20.
20. Tlali M, Fielding KL, Karat AS, Hoffmann CJ, Muravha T, Grant AD, et al. Sensitivity of the lateral flow urine lipoarabinomannan assay in ambulant adults with advanced HIV disease: Data from the TB Fast Track study. Trans R Soc Trop Med Hyg. 2020;114(8):556–60.
21. Ogundeji AA, Ahmadu I, Awotoye J, Ogwu J, Laraban S, Ajobiewe J, et al. Evaluation of diagnostic accuracy of TB LAM rapid urine antigen screening assay, GeneXpert and smear microscopy for TB and HIV co-infected population in the Guinea Savannah Zone of Nigeria. Texila International Journal of Public Health. 2018;6(4):3.
22. Irawan GC, Margawati A, Rosidi A. Underweight increases the risk of pulmonary tuberculosis in adult. Universa Medicina. 2017;36(1):4–10.
23. Zhang Y, Chen S, Wei H, Zhong Q, Yuan Y, Wang Y, et al. Breakthrough of chemiluminescence-based LAM urine test beyond HIV-positive individuals: Clinical diagnostic value of pulmonary tuberculosis in the general population. Medicine. 2023;102(48):e36371.
24. Suwanpimolkul G, Kawkitinarong K, Manosuthi W, Sophonphan J, Gatechompol S, Ohata PJ, et al. Utility of urine lipoarabinomannan (LAM) in diagnosing tuberculosis and predicting mortality with and without HIV: Prospective TB cohort from the Thailand Big City TB Research Network. International Journal of Infectious Diseases. 2017;59:96–102.
25. Global Laboratory Initiative. Practical implementation of LF-LAM for detection of active TB in people living with HIV. 2019.
26. Wang X, Chen J, Zeng Y, Ma Q, Kong X, Meng J, et al. Interpretation of the third edition of WHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection. Chinese Journal of Antituberculosis. 2024;46(9):1006–22.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Dwi Robbiardy Eksa, Gatot Sudiro Hendarto, Fransisca TY Sinaga, Pad Dilangga, M. Junus Didiek Herdato, Andreas Infianto, Diyan Ekawati, Achmad Gozali, Adhari Ajipurnomo
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
